- Home
- CELC vs UTG Comparison
CELC vs UTG Comparison
Compare CELC & UTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELC | UTG |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2017 | 2003 |
Fundamental Metrics
Financial Performance| Metric | CELC | UTG |
|---|---|---|
| Price | $114.71 | $40.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $107.88 | N/A |
| AVG Volume (30 Days) | ★ 646.7K | 211.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $706.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.61 | $28.40 |
| 52 Week High | $120.32 | $42.35 |
Technical Indicators
Market Signals| Indicator | CELC | UTG |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 52.82 |
| Support Level | $99.38 | $38.52 |
| Resistance Level | $117.61 | $41.89 |
| Average True Range (ATR) | 6.16 | 0.80 |
| MACD | 0.41 | 0.03 |
| Stochastic Oscillator | 80.51 | 66.42 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.